Jacobus Johannes Maria van Dongen,José Alberto Orfao de Matos Correia e Vale,Juan Alejandro Flores Montero,Julia Maria Almeida Parra,Vincent Henricus Johannes Van der Velden,Sebastian Böttcher,Anthoni
申请号：
US15812384
公开号：
US20180140664A1
申请日:
2017.11.14
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ≥8-color flow cytometric stainings as well as for 10-color and 12-color flow cyometric stainings, which can reach sensitivities of at least 10−4, even down to 10−5. Also provided are diagnostic kits and methods for detecting MRD.
